SG11201703152RA - Reducing viscosity of pharmaceutical formulations - Google Patents
Reducing viscosity of pharmaceutical formulationsInfo
- Publication number
- SG11201703152RA SG11201703152RA SG11201703152RA SG11201703152RA SG11201703152RA SG 11201703152R A SG11201703152R A SG 11201703152RA SG 11201703152R A SG11201703152R A SG 11201703152RA SG 11201703152R A SG11201703152R A SG 11201703152RA SG 11201703152R A SG11201703152R A SG 11201703152RA
- Authority
- SG
- Singapore
- Prior art keywords
- pharmaceutical formulations
- reducing viscosity
- viscosity
- reducing
- formulations
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462067637P | 2014-10-23 | 2014-10-23 | |
| PCT/US2015/056972 WO2016065181A1 (en) | 2014-10-23 | 2015-10-22 | Reducing viscosity of pharmaceutical formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201703152RA true SG11201703152RA (en) | 2017-05-30 |
Family
ID=54427875
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201703152RA SG11201703152RA (en) | 2014-10-23 | 2015-10-22 | Reducing viscosity of pharmaceutical formulations |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US11813328B2 (enExample) |
| EP (2) | EP3909611B1 (enExample) |
| JP (3) | JP2017531682A (enExample) |
| KR (1) | KR102534017B1 (enExample) |
| CN (2) | CN114569716A (enExample) |
| AU (2) | AU2015335743B2 (enExample) |
| BR (1) | BR112017008125B1 (enExample) |
| CA (1) | CA2964786C (enExample) |
| CL (2) | CL2017000984A1 (enExample) |
| EA (3) | EA202191513A1 (enExample) |
| ES (1) | ES2964713T3 (enExample) |
| IL (2) | IL287947B2 (enExample) |
| MA (1) | MA54716A (enExample) |
| MX (2) | MX388858B (enExample) |
| SG (1) | SG11201703152RA (enExample) |
| WO (1) | WO2016065181A1 (enExample) |
| ZA (1) | ZA201702762B (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017531682A (ja) | 2014-10-23 | 2017-10-26 | アムジエン・インコーポレーテツド | 医薬製剤の粘度低下 |
| EP3522918A1 (en) * | 2016-10-06 | 2019-08-14 | Amgen Inc. | Reduced viscosity protein pharmaceutical formulations |
| JP7377596B2 (ja) | 2017-02-22 | 2023-11-10 | アムジエン・インコーポレーテツド | 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法 |
| AU2018258676B2 (en) * | 2017-04-28 | 2024-09-19 | Amgen Inc. | N-acetylated and non-acetylated dipeptides containing arginine to reduce the viscosity of viscous compositions of therapeutic polypeptides |
| EP3615065A1 (en) | 2017-04-28 | 2020-03-04 | Amgen Inc. | Excipients to reduce the viscosity of antibody formulations and formulation compositions |
| US10646569B2 (en) | 2017-05-16 | 2020-05-12 | Bhami's Research Laboratory, Pvt. Ltd. | High concentration protein formulations with reduced viscosity |
| PE20200678A1 (es) | 2017-06-16 | 2020-06-11 | Zealand Pharma As | Posologias para la administracion de analogos de peptido de tipo glucagon-2 (glp-2) |
| EP3685849A4 (en) * | 2017-09-22 | 2021-12-22 | Asahi Kasei Pharma Corporation | LIQUID PHARMACEUTICAL COMPOSITION CONTAINING TERIPARATIDE WITH EXCELLENT STABILITY |
| WO2019106206A1 (en) | 2017-12-01 | 2019-06-06 | Fyb 202 Project Gmbh | Stable, low viscosity, high concentration liquid formulations of an anti-il-12/23p40 antibody |
| AU2019297498A1 (en) | 2018-07-05 | 2021-01-21 | Bayer Aktiengesellschaft | Method for the production of freeze-dried pellets comprising an anti-coagulation factor xia (FXIa) antibody |
| EP3774841A1 (en) | 2018-08-27 | 2021-02-17 | Regeneron Pharmaceuticals, Inc. | Use of raman spectroscopy in downstream purification |
| EP3628683A1 (en) * | 2018-09-28 | 2020-04-01 | Zealand Pharma A/S | Formulations of glucagon-like-peptide-2 (glp-2) analogues |
| JP7739182B2 (ja) * | 2019-04-23 | 2025-09-16 | アムジエン・インコーポレーテツド | 高濃度タンパク質製剤の粘度を低減させるための低分子量ポリビニルピロリドン（ｐｖｐ）の使用 |
| CA3166964A1 (en) * | 2020-02-13 | 2021-08-19 | Alexis Lueras | Formulations of human anti-tslp antibodies and methods of treating inflammatory disease |
| KR102746418B1 (ko) * | 2020-12-03 | 2024-12-26 | 동국대학교 산학협력단 | N-아세틸-l-아르기닌을 포함하는 단백질 응집 억제용 조성물 |
| MX2023010457A (es) * | 2021-03-09 | 2023-09-14 | Gi Innovation Inc | Formulacion de proteina de fusion que incluye el dominio extracelular de la subunidad alfa del receptor fc de ige. |
| EP4319795A4 (en) * | 2021-04-09 | 2025-03-05 | Avantor Performance Materials, LLC | Performance-enhancing excipients and methods of reducing viscosity and increasing stability of biologic formulations |
| WO2025175164A1 (en) * | 2024-02-16 | 2025-08-21 | Regeneron Pharmaceuticals, Inc. | Methods of producing concentrated formulated drug substances comprising proteins, and concentrated formulated drug substance made by the methods |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5078997A (en) | 1988-07-13 | 1992-01-07 | Cetus Corporation | Pharmaceutical composition for interleukin-2 containing physiologically compatible stabilizers |
| US5955448A (en) | 1994-08-19 | 1999-09-21 | Quadrant Holdings Cambridge Limited | Method for stabilization of biological substances during drying and subsequent storage and compositions thereof |
| US6767892B1 (en) * | 1997-11-07 | 2004-07-27 | Chrion Corporation | Compositions providing for increased IGF-I solubility |
| DE69814133T2 (de) | 1997-11-07 | 2004-04-01 | Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville | Zusammensetzung um die löslichkeit von igf-i zu erhöhen |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| US6159485A (en) * | 1999-01-08 | 2000-12-12 | Yugenic Limited Partnership | N-acetyl aldosamines, n-acetylamino acids and related n-acetyl compounds and their topical use |
| EP1273306A4 (en) | 2000-03-31 | 2005-06-22 | Kirin Brewery | POWDER PREPARATION FOR TRANSMUCOSAL ADMINISTRATION CONTAINING A POLYMERIC FORM OF AN ACTIVE SUBSTANCE AND HAVING AN IMPROVED STORAGE STABILITY |
| AU2002230707B2 (en) | 2000-11-07 | 2006-08-24 | Novartis Vaccines And Diagnostics, Inc. | Stabilized interferon compositions |
| CN100557018C (zh) | 2001-08-23 | 2009-11-04 | 根马布股份公司 | 白介素15(il-15)特异性人抗体 |
| WO2003072060A2 (en) | 2002-02-27 | 2003-09-04 | Immunex Corporation | Polypeptide formulation |
| AU2003293543A1 (en) | 2002-12-13 | 2004-07-09 | Abgenix, Inc. | System and method for stabilizing antibodies with histidine |
| JP2006516636A (ja) | 2003-01-30 | 2006-07-06 | メディミューン，インコーポレーテッド | 抗インテグリンαｖβ３抗体製剤及びその用途 |
| RU2332986C2 (ru) | 2003-04-04 | 2008-09-10 | Дженентек, Инк. | Высококонцентрированные композиции антител и белков |
| US8084032B2 (en) | 2004-01-21 | 2011-12-27 | Ajinomoto Co., Inc. | Purification method which prevents denaturation of an antibody |
| US20060051347A1 (en) | 2004-09-09 | 2006-03-09 | Winter Charles M | Process for concentration of antibodies and therapeutic products thereof |
| WO2006081171A1 (en) | 2005-01-24 | 2006-08-03 | Amgen Inc. | Humanized anti-amyloid antibody |
| US7592429B2 (en) | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
| US8003108B2 (en) | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
| WO2007074880A1 (ja) * | 2005-12-28 | 2007-07-05 | Chugai Seiyaku Kabushiki Kaisha | 抗体含有安定化製剤 |
| CN101426527A (zh) * | 2006-02-03 | 2009-05-06 | 米迪缪尼有限公司 | 蛋白质制剂 |
| GB0603683D0 (en) | 2006-02-23 | 2006-04-05 | Novartis Ag | Organic compounds |
| AU2007249349B2 (en) | 2006-05-11 | 2012-03-08 | Isis Pharmaceuticals, Inc. | 5'-Modified bicyclic nucleic acid analogs |
| PH12013500356A1 (en) | 2006-12-14 | 2021-08-09 | Schering Corp | Engineered anti-tslp antibody |
| WO2008155365A1 (en) | 2007-06-20 | 2008-12-24 | Irm Llc | Methods and compositions for treating allergic diseases |
| JOP20080381B1 (ar) | 2007-08-23 | 2023-03-28 | Amgen Inc | بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9) |
| US7982016B2 (en) | 2007-09-10 | 2011-07-19 | Amgen Inc. | Antigen binding proteins capable of binding thymic stromal lymphopoietin |
| NZ585702A (en) | 2007-11-30 | 2013-08-30 | Abbott Lab | Protein formulations and methods of making same |
| AU2009204863B2 (en) * | 2008-01-15 | 2015-07-16 | AbbVie Deutschland GmbH & Co. KG | Powdered protein compositions and methods of making same |
| TWI516501B (zh) | 2008-09-12 | 2016-01-11 | 禮納特神經系統科學公司 | Ｐｃｓｋ９拮抗劑類 |
| JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| JP2011067202A (ja) | 2009-08-31 | 2011-04-07 | Sanyo Chem Ind Ltd | タンパク質水溶液の安定化剤、この安定化剤を含有するタンパク質水溶液及びタンパク質の安定化方法 |
| CA2780554C (en) * | 2009-11-17 | 2017-08-15 | Ipsen Pharma S.A.S. | Formulation for hgh and rhigf-1 combination |
| US9241897B2 (en) | 2010-02-04 | 2016-01-26 | Csl Behring Ag | Immunoglobulin preparation |
| CN107693791B (zh) * | 2010-02-26 | 2022-06-07 | 诺沃—诺迪斯克有限公司 | 包含稳定抗体的组合物 |
| WO2011109415A2 (en) * | 2010-03-02 | 2011-09-09 | Amgen Inc. | Reducing viscosity of pharmaceutical formulations |
| JP2013525484A (ja) * | 2010-05-03 | 2013-06-20 | ジェネンテック， インコーポレイテッド | タンパク質含有製剤の粘度を低減させるために有用な組成物及び方法 |
| AR083495A1 (es) | 2010-10-22 | 2013-02-27 | Esbatech Alcon Biomed Res Unit | Anticuerpos estables y solubles |
| JOP20200043A1 (ar) | 2011-05-10 | 2017-06-16 | Amgen Inc | طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول |
| US9574005B2 (en) | 2011-07-19 | 2017-02-21 | Chugai Seiyaku Kabushiki Kaisha | Stable Protein-containing preparation containing argininamide or analogous compound thereof |
| AU2012328524B2 (en) * | 2011-10-28 | 2017-05-18 | Excelse Bio, Inc. | Protein formulations containing amino acids |
| EA039663B1 (ru) | 2012-05-03 | 2022-02-24 | Амген Инк. | Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств |
| JP2015519382A (ja) | 2012-06-12 | 2015-07-09 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 治療用抗体のための医薬処方物 |
| US20150004174A1 (en) | 2013-06-28 | 2015-01-01 | Amgen Inc. | Methods for treating homozygous familial hypercholesterolemia |
| TWI694836B (zh) | 2014-05-16 | 2020-06-01 | 英商葛蘭素史克智慧財產管理有限公司 | 抗體調配物 |
| JP2017531682A (ja) | 2014-10-23 | 2017-10-26 | アムジエン・インコーポレーテツド | 医薬製剤の粘度低下 |
| HUE052280T2 (hu) | 2014-12-03 | 2021-04-28 | Csl Behring Ag | Immunoglobulinokat tartalmazó megnövelt stabilitású gyógyszerészeti termék |
| IL265692B2 (en) | 2016-09-29 | 2024-03-01 | Amgen Inc | Low-viscosity antigen binding proteins and methods of making them |
| EP3522918A1 (en) | 2016-10-06 | 2019-08-14 | Amgen Inc. | Reduced viscosity protein pharmaceutical formulations |
| JP7377596B2 (ja) | 2017-02-22 | 2023-11-10 | アムジエン・インコーポレーテツド | 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法 |
-
2015
- 2015-10-22 JP JP2017522169A patent/JP2017531682A/ja active Pending
- 2015-10-22 EA EA202191513A patent/EA202191513A1/ru unknown
- 2015-10-22 CN CN202210048275.7A patent/CN114569716A/zh active Pending
- 2015-10-22 ES ES21175309T patent/ES2964713T3/es active Active
- 2015-10-22 CN CN201580057461.5A patent/CN107206070B/zh active Active
- 2015-10-22 EA EA201790787A patent/EA033444B1/ru not_active IP Right Cessation
- 2015-10-22 CA CA2964786A patent/CA2964786C/en active Active
- 2015-10-22 AU AU2015335743A patent/AU2015335743B2/en active Active
- 2015-10-22 MX MX2017005243A patent/MX388858B/es unknown
- 2015-10-22 US US15/521,057 patent/US11813328B2/en active Active
- 2015-10-22 EP EP21175309.0A patent/EP3909611B1/en active Active
- 2015-10-22 SG SG11201703152RA patent/SG11201703152RA/en unknown
- 2015-10-22 EA EA201991447A patent/EA038462B1/ru unknown
- 2015-10-22 MA MA054716A patent/MA54716A/fr unknown
- 2015-10-22 WO PCT/US2015/056972 patent/WO2016065181A1/en not_active Ceased
- 2015-10-22 BR BR112017008125-3A patent/BR112017008125B1/pt active IP Right Grant
- 2015-10-22 IL IL287947A patent/IL287947B2/en unknown
- 2015-10-22 EP EP15790759.3A patent/EP3209332B1/en active Active
- 2015-10-22 KR KR1020177011706A patent/KR102534017B1/ko active Active
-
2017
- 2017-04-13 IL IL251726A patent/IL251726B/en unknown
- 2017-04-19 ZA ZA2017/02762A patent/ZA201702762B/en unknown
- 2017-04-20 CL CL2017000984A patent/CL2017000984A1/es unknown
- 2017-04-21 MX MX2021015789A patent/MX2021015789A/es unknown
-
2019
- 2019-08-02 CL CL2019002190A patent/CL2019002190A1/es unknown
- 2019-10-21 JP JP2019191701A patent/JP6965321B2/ja active Active
-
2021
- 2021-02-15 AU AU2021200990A patent/AU2021200990B2/en active Active
- 2021-10-19 JP JP2021170676A patent/JP7411615B2/ja active Active
-
2023
- 2023-10-24 US US18/383,121 patent/US12318447B2/en active Active
-
2025
- 2025-05-30 US US19/223,578 patent/US20250345421A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL287947A (en) | Viscosity reduction of pharmaceutical preparations | |
| IL246978A0 (en) | New paracetamol formulations | |
| ZA201605300B (en) | Pharmaceutical compositions comprising azd9291 | |
| GB201618482D0 (en) | Pharmaceutical compositions | |
| GB201419257D0 (en) | Pharmaceutical compositions | |
| GB201409471D0 (en) | Pharmaceutical composition | |
| IL249553A0 (en) | Pharmaceutical preparations | |
| GB201409488D0 (en) | Pharmaceutical composition | |
| GB201409485D0 (en) | Pharmaceutical composition | |
| ZA201606075B (en) | Pharmaceutical compositions of sitagliptin | |
| IL256115A (en) | Pharmaceutical formulations of injectable lapmoline | |
| HUE039791T2 (hu) | Levocetirizint tartalmazó gyógyszerészeti készítmények | |
| IL250817A0 (en) | pharmaceutical preparations | |
| IL267279A (en) | Pharmaceutical formulations of suvorexant | |
| GB201718468D0 (en) | Stable liquid pharmaceutical compositions of bortezomb | |
| PT3200772T (pt) | Composições farmacêuticas compreendendo alpelisib | |
| GB201506755D0 (en) | Novel pharmaceutical formulation | |
| LT3089740T (lt) | Farmacinė kompozicija | |
| GB2529605B (en) | Pharmaceutical composition | |
| GB201417589D0 (en) | Pharmaceutical Formulations | |
| HK1242572A1 (en) | Reducing viscosity of pharmaceutical formulations | |
| GB201407741D0 (en) | Novel drug formulation | |
| GB201400951D0 (en) | Novel drug formulation | |
| SG2014014872A (en) | Pharmaceutical compositions | |
| GB201408432D0 (en) | Pharmaceutical compositions |